Search hospitals > New Mexico > Las Cruces

Memorial Medical Center - Las Cruces

Claim this profile
Las Cruces, New Mexico 88011
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
108 reported clinical trials
13 medical researchers
Photo of Memorial Medical Center - Las Cruces in Las CrucesPhoto of Memorial Medical Center - Las Cruces in Las CrucesPhoto of Memorial Medical Center - Las Cruces in Las Cruces

Summary

Memorial Medical Center - Las Cruces is a medical facility located in Las Cruces, New Mexico. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Memorial Medical Center - Las Cruces is involved with conducting 108 clinical trials across 261 conditions. There are 13 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.

Area of expertise

1Breast Cancer
Global Leader
Memorial Medical Center - Las Cruces has run 29 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive
2Lung Cancer
Global Leader
Memorial Medical Center - Las Cruces has run 24 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage III

Top PIs

Clinical Trials running at Memorial Medical Center - Las Cruces

Lung Cancer
Breast Cancer
Cancer
Colorectal Cancer
Bladder Cancer
Lymphoma
Pancreatic Cancer
Prostate Cancer
Multiple Myeloma
Chronic Lymphocytic Leukemia
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Memorial Medical Center - Las Cruces?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security